Biotechnology Advances | VOL. 39
Read

A critical review on exploiting the pharmaceutical potential of plant endophytic fungi

Publication Date Mar 1, 2020

Abstract

The escalating demand for secondary metabolites in international markets poses a severe threat to many plant species. An unscrupulous collection is also the immediate challenge to the survival of many unthreatened as well as vulnerable plants. Fungal endophytes have emerged in recent years as a promising substitute for sources of plant secondary metabolites. Many appealing secondary metabolites with potent antibacterial, antifungal, insecticidal, antioxidant, cytotoxic and anticancer properties have been discovered from endophytic fungi. Concerning their distinctive genetic and metabolic diversity and promising activities, they hold a plausible application in medicine and industry. However, there is little success in utilizing the pharmaceutical potential of fungal endophytes. Cutting-edge research is desirable to establish and bolster in vitro biosynthetic proficiency of fungal endophytes. Modern biotechnological techniques [such as multilocus sequence typing (MLST), metabolomics, metagenomics and next-generation sequencing (NGS) technologies] and bioinformatics approaches can fill a gap in fungal endophyte research. The present review focuses on how advanced chemical, biotechnological and computational molecular biology methods can be used for robust exploitation of bioactive compounds from these microorganisms.

Concepts

Modern Biotechnological Techniques Fungal Endophytes Vulnerable Plants Secondary Metabolites Multilocus Sequence Typing Metabolic Diversity Application In Medicine Bioinformatics Approaches Chemical Biology Methods Anticancer Properties

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Nov 21, 2022 to Nov 27, 2022

R DiscoveryNov 28, 2022
R DiscoveryArticles Included:  2

No potential conflict of interest was reported by the authors. The conception and design of the study, acquisition of data, analysis and interpretatio...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on “as is” basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The Copyright Law.